Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Gap Down – Time to Sell?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) gapped down prior to trading on Tuesday . The stock had previously closed at $24.59, but opened at $22.57. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.0760, with a volume of 508,488 shares trading hands.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on FMS. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. The Goldman Sachs Group lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Erste Group Bank lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Finally, Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Five equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Trading Down 7.9%

The firm has a market capitalization of $13.13 billion, a P/E ratio of 16.53, a PEG ratio of 0.77 and a beta of 0.90. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The stock has a fifty day simple moving average of $23.34 and a 200 day simple moving average of $24.48.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $0.67 by $1.02. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. As a group, research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.4% in the fourth quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock valued at $212,000 after purchasing an additional 450 shares in the last quarter. GAMMA Investing LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 5.9% during the third quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock worth $275,000 after buying an additional 585 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after purchasing an additional 699 shares during the period. Fifth Third Bancorp increased its position in Fresenius Medical Care AG & Co. KGaA by 4.0% during the fourth quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock worth $447,000 after purchasing an additional 726 shares during the last quarter. Finally, Arax Advisory Partners raised its stake in Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.